Dengue vaccine study aims to unlock immune secrets

NCT ID NCT07158190

Ongoing Knowledge-focused Sponsor: Fondazione Policlinico Universitario Agostino Gemelli IRCCS Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 26, 2026

Summary

This study looks at how the Takeda dengue vaccine (TAK-003) activates T-cells, a key part of the immune system. Researchers will vaccinate 30 healthy adults and analyze their T-cell and antibody responses over 26 weeks. The goal is to find reliable markers of protection, which could improve future dengue vaccines and help prevent severe disease.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: TAK003 (live attenuated tetravalent dengue vaccine)
What this could lead to: If successful, this could identify immune markers that predict protection, helping improve dengue vaccines and reduce severe disease risk.
What could go wrong: This is a small, early-stage study (30 participants) focused on immune responses, not on proving the vaccine works. Results may not apply to larger populations or real-world settings.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for DENGUE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

dengue disease prevention target

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

DENGUE

Contacts and locations

Locations

Fondazione Policlinico Universtiario Agostino Gemelli IRCCS

Rome, Roma, 00168, Italy

More trials for these conditions

Other studies related to the condition(s) this trial covers.